Milestone Pharmaceuticals Files 8-K

Ticker: MIST · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1408443

Sentiment: neutral

Topics: 8-K, disclosure, financials

TL;DR

Milestone Pharma filed an 8-K on 12/15 for events on 12/12, covering Reg FD, other events, and financials.

AI Summary

Milestone Pharmaceuticals Inc. filed an 8-K on December 15, 2025, reporting events that occurred on December 12, 2025. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company is incorporated in Quebec and its principal executive offices are located in Montreal.

Why It Matters

This 8-K filing indicates that Milestone Pharmaceuticals Inc. is disclosing important corporate events and financial information to the public, which could impact investor decisions.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain any immediate negative news or significant financial distress.

Key Players & Entities

FAQ

What specific events are being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the provided text.

What are the 'Other Events' being reported by Milestone Pharmaceuticals Inc.?

The filing lists 'Other Events' as a category, but the specific nature of these events is not detailed in the provided excerpt.

What is the significance of the 'Financial Statements and Exhibits' being filed?

This indicates that financial information and supporting documents are being submitted as part of the 8-K filing, which could include recent financial performance or material agreements.

When was Milestone Pharmaceuticals Inc. incorporated and where?

Milestone Pharmaceuticals Inc. is incorporated in Quebec, Canada, as indicated by the filing.

What is the principal business address of Milestone Pharmaceuticals Inc.?

The principal executive offices are located at 1111 Dr. Frederik-Philips Boulevard, Suite 420, Montreal, Quebec, CA H4M 2X6.

Filing Stats: 695 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-12-15 08:56:24

Filing Documents

01

Item 7.01. Regulation FD Disclosure. On December 15, 2025 , Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") provided a corporate presentation that may be used in connection with presentations at conferences and investor meetings. The full text of the Company's corporate presentation is filed as Exhibit 99.1 hereto, and incorporated herein by reference, and may also be accessed through the "Investors & Media" section of the Company's website at www.milestonepharma.com . The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on its website in the "Investors & Media" section. Accordingly, investors should monitor such portions of its website, in addition to following press releases, filings with the U.S. Securities Exchange Commission (the "SEC") and public conference calls and webcasts. The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, or the Securities Act. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing with the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01

Item 8.01 Other Events On December 12, 2025, the Company issued a press release announcing that the U.S. Food and Drug Administration has approved the Company's New Drug Application for CARDAMYST (etripamil) nasal spray for the management of paroxysmal supraventricular tachycardia (PSVT). A copy of the press release is filed herewith as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description of Exhibit 99.1 Corporate Presentation, dated D ecember 15, 2025 99.2 Press Release dated D ecember 12, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MILESTONE PHARMACEUTICALS INC. By: /s/Amit Hasija Amit Hasija Chief Financial Officer Dated: December 15, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing